Laura Michaelis, MD

Laura Michaelis, MD, discusses the next steps for research in the treatment of myelofibrosis following the addition of fedratinib to the armamentarium of JAK inhibitors.

Laura Michaelis, MD, discusses how to select patients with either polycythemia vera or essential thrombocythemia for cytoreductive therapy.

Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses thrombotic risk for patients with essential thrombocythemia and polycythemia vera.